Loading stock data…
LFWD
$7.25-0.04 (-0.48%)
Market ClosedLast close May 1
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lifeward Ltd. in the Healthcare sector is trading at $7.25. The stock is currently 59% below its 52-week high of $17.76, remaining 3.0% below its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why LFWD maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 65) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.25
Potential Upside
5%
Whystock Fair Value$7.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$20.00+176.1%
Range$10.00 – $30.00
Fundamentals
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Ger...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-236.85%
Volume
Today's trading volume
3,525
Recent News
Lifeward Ltd (LFWD) Q4 2025 Earnings Call Highlights: Strategic Moves and Market Challenges
Lifeward Ltd (LFWD) outlines its path to becoming a diversified biomedical leader amid revenue declines and strategic transformations.
Lifeward: Q4 Earnings Snapshot
MARLBOROUGH, Mass. AP) — Lifeward Ltd. (LFWD) on Wednesday reported a loss of $5.3 million in its fourth quarter. On a per-share basis, the Marlborough, Massachusetts-based company said it had a loss of $3.60.
Lifeward Ltd (LFWD) Q4 2025: Everything You Need To Know Ahead Of Earnings
This article first appeared on GuruFocus. Lifeward Ltd (NASDAQ:LFWD) is set to release its Q4 2025 earnings on Mar 18, 2026. The consensus estimate for Q4 2025 revenue is $7.86 million, and the earnings are expected to come in at -$1.08 per share.
Lifeward Ltd (LFWD) Q3 2025 Earnings Call Highlights: Navigating Growth and Challenges
Lifeward Ltd (LFWD) reports modest revenue growth, strategic advancements, and financial hurdles in its Q3 2025 earnings call.
Lifeward (LFWD) Q3 2025 Earnings Call Transcript
William Mark Grant: Thank you, Almog. Since joining Lifeward Ltd. in June, I have completed a sober and comprehensive assessment of the business, starting with our strategic direction down to our commercial model and operations.